Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study.
Journal: American journal of respiratory and critical care medicine
Published: June 13, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study.
Journal: American journal of respiratory and critical care medicine
Published: June 02, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3 Open-Label Extension Study.
Journal: American journal of respiratory and critical care medicine
Published: April 10, 2025
Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: August 11, 2024
Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events.
Journal: American journal of respiratory and critical care medicine
Published: October 27, 2023
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial.
Journal: American journal of respiratory and critical care medicine
Published: May 08, 2023
Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.
Journal: The Lancet. Respiratory medicine
Published: September 29, 2022
Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.
Journal: The New England journal of medicine
Published: August 26, 2021
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Journal: The Lancet. Respiratory medicine
Published: July 01, 2021
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele.
Journal: American journal of respiratory and critical care medicine
Published: March 18, 2021
Transparency and diversity in cystic fibrosis research - Authors' reply.
Journal: Lancet (London, England)
Published: March 12, 2020
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
Journal: The New England journal of medicine
Published: November 08, 2019
Last Updated: 09/26/2026